Time to workforce exit after a Parkinson's disease diagnosis.
Jonathan TimpkaÖrjan DahlströmMaria H NilssonSusanne IwarssonPer OdinPublished in: NPJ Parkinson's disease (2023)
The impact of Parkinson's disease (PD) on workforce participation has received little attention even though demographic, lifestyle, and political changes together will result in an increased burden of PD on the working-age population. In this study, we investigate workforce survival after a PD diagnosis, as well as what demographic factors that are associated with workforce survival. As an exploratory outcome, we investigate workforce survival in persons with and without device-aided treatment (DAT). This is a nested case-cohort study based on Swedish national data from 2001-2016. Controls were matched on year of birth, sex, and municipality of residence. The used registers contain data on demographics, social insurance, in- and outpatient visits, filled drug prescriptions, and cause of death on the person-level. A total of 4781 persons with PD and 23,905 controls were included. The median survival until all-cause workforce exit was 43 months among persons that were workforce-active at the time of PD diagnosis, compared to 66 months in non-PD controls. Being female, ≥50 years old at diagnosis, or having a lower education were contributing factors to health-related workforce exit. Persons receiving DAT during follow-up exhibited shorter workforce survival than controls. However, this needs further investigation, particularly as patients have generally already left the workforce at the time for start of DAT. It is evident that PD has grave negative effects on workforce participation. Thus, supportive measures need to start at an early stage after diagnosis, and the development of new interventions is urgently needed.
Keyphrases
- public health
- early stage
- healthcare
- physical activity
- end stage renal disease
- mental health
- quality improvement
- squamous cell carcinoma
- radiation therapy
- peritoneal dialysis
- big data
- pregnant women
- neoadjuvant chemotherapy
- electronic health record
- risk factors
- artificial intelligence
- chronic kidney disease
- ejection fraction
- patient reported outcomes
- rectal cancer
- emergency department
- weight loss